Efficacy of breast-conserving surgery and modified radical mastectomy combined with neoadjuvant chemotherapy in treatment of breast cancer

LI Wei; ZHANG Tao-tao; ZHANG Wei; WANG Hai-chao; CUI Xiao-chen

doi:10.11659/jjssx.09E025099

您当前的位置：

首页 >

文章列表页 >

Efficacy of breast-conserving surgery and modified radical mastectomy combined with neoadjuvant chemotherapy in treatment of breast cancer

Precise Diagnosis and Treatment of Breast and Thyroid Diseases | 更新时间：2026-07-31

- Efficacy of breast-conserving surgery and modified radical mastectomy combined with neoadjuvant chemotherapy in treatment of breast cancer
- JOURNAL OF REGIONAL ANATOMY AND OPERATIVE SURGERY Vol. 35, Issue 8, Pages: 674-677(2026)
- 作者机构：
  
  西安市人民医院/西安市第四医院普通外科，陕西西安 710000
- 作者简介：
- 基金信息：
- DOI：10.11659/jjssx.09E025099
  CLC： R737.9
- Received：25 September 2025，
  
  Online First：31 July 2026，
  
  Published：25 August 2026
- 稿件说明：
移动端阅览
李伟,张涛涛,张伟等.保乳术和改良根治术联合新辅助化疗治疗乳腺癌的效果分析[J].局解手术学杂志,2026,35(08):674-677.

LI Wei,ZHANG Tao-tao,ZHANG Wei,et al.Efficacy of breast-conserving surgery and modified radical mastectomy combined with neoadjuvant chemotherapy in treatment of breast cancer[J].JOURNAL OF REGIONAL ANATOMY AND OPERATIVE SURGERY,2026,35(08):674-677.
李伟,张涛涛,张伟等.保乳术和改良根治术联合新辅助化疗治疗乳腺癌的效果分析[J].局解手术学杂志,2026,35(08):674-677. DOI： 10.11659/jjssx.09E025099.

LI Wei,ZHANG Tao-tao,ZHANG Wei,et al.Efficacy of breast-conserving surgery and modified radical mastectomy combined with neoadjuvant chemotherapy in treatment of breast cancer[J].JOURNAL OF REGIONAL ANATOMY AND OPERATIVE SURGERY,2026,35(08):674-677. DOI： 10.11659/jjssx.09E025099.

摘要

目的

探讨保乳术和改良根治术联合新辅助化疗治疗乳腺癌的效果。

方法

回顾性分析我院接受保乳术或改良根治术联合新辅助化疗治疗的200例乳腺癌女性患者的临床资料，根据手术方案将患者分为保乳术组（92例）和根治术组（108例）。保乳术组患者接受保乳术联合新辅助化疗治疗，根治术组患者接受改良根治术联合新辅助化疗治疗。比较2组患者手术指标、血清肿瘤标志物、生活质量、无进展生存期和并发症情况。

结果

与根治术组比较，保乳术组患者术中出血量减少，引流管引流时间和住院时间缩短，差异均有统计学意义（

0.05）。2组患者治疗后3个月的癌胚抗原（CEA）、糖类抗原125（CA125）、糖类抗原153（CA153）和血管内皮生长因子（VEGF）水平比较，差异无统计学意义（

0.05）。2组患者治疗后12个月SF-36量表各维度评分比较，差异无统计学意义（

0.05）。保乳术组和根治术组患者的中位无进展生存期分别为56个月（95%

：50.18~61.82）和64个月（95%

：44.15~83.86），差异无统计学意义（

0.05）。保乳术组患者术后并发症总发生率低于根治术组（

0.05）。

结论

保乳术或改良根治术联合新辅助化疗治疗乳腺癌患者的疗效相当，但保乳术损伤更轻、并发症更少。

Abstract

Objective

To explore the efficacy of breast-conserving surgery and modified radical mastectomy combined with neoadjuvant chemotherapy in the treatment of breast cancer.

Methods

A retrospective study was conducted on the clinical data of 200 female breast cancer patients who received breast-conserving surgery or modified radical mastectomy combined with neoadjuvant chemotherapy in our hospital. According to the surgical plan， the patients were divided into the breast-conserving surgery group （92 cases） and the radical mastectomy group （108 cases）. Patients in the breast-conserving surgery group received breast-conserving surgery combined with neoadjuvant chemotherapy， while patients in the radical mastectomy group received modified radical mastectomy combined with neoadjuvant chemotherapy. The surgical indicators， serum tumor markers， quality of life， progression-free survival and complications of patients between the two groups were compared.

Results

Compared with the radical mastectomy group， the intraoperative blood loss of patients in the breast-conserving surgery group was reduced， the drainage time of the drainage tube and the hospital stay were shortened， and the differences were statistically significant （

0.05）. There were no statistically significant differences in the levels of carcinoembryonic antigen （CEA）， carbohydrate antigen 125 （CA125）， carbohydrate antigen 153 （CA153）， and vascular endothelial growth factor （VEGF） between the two groups of patients 3 months after treatment （

0.05）. There were no statistically significant differences in the scores of each dimension of the SF-36 scale between the two groups of patients 12 months after treatment （

0.05）. The median progression-free survivals of patients in the breast-conserving surgery group and the radical mastectomy group were 56 months （95%

： 50.18 to 61.82） and 64 months （95%

： 44.15 to 83.86）， respectively， and the difference was not statistically significant （

0.05）. The total incidence of postoperative complications in the breast-conserving surgery group was lower than that in the radical mastectomy group （

0.05）.

Conclusion

Breast-conserving surgery or modified radical mastectomy combined with neoadjuvant chemotherapy has similar efficacy in the treatment of breast cancer patients， but breast-conserving surgery has the advantages of less damage and fewer complications.

关键词

Keywords

references

王稚晴，刘西禹，范蕾 . 早期乳腺癌辅助治疗的进展和争议［J］. 中国癌症杂志， 2025 ， 35 （ 3 ）： 255 - 262 . doi： 10.19401/j.cnki.1007-3639.2025.03.001 http://dx.doi.org/10.19401/j.cnki.1007-3639.2025.03.001 .

高汉晶，杨丽，闫争，等 . pT1~2N1M0期乳腺癌改良根治术后患者预后预测模型的构建［J］. 临床放射学杂志， 2025 ， 44 （ 3 ）： 429 - 434 .

储诚森，陈曦，夏苗火，等 . 基于术前MRI影像参数预测早期乳腺癌保乳术治疗结局的价值［J］. 中国医学计算机成像杂志， 2025 ， 31 （ 2 ）： 178 - 185 . doi： 10.3969/j.issn.1006-5741.2025.02.007 http://dx.doi.org/10.3969/j.issn.1006-5741.2025.02.007 .

夏坤健，王琳，唐娜，等 . 三阴性乳腺癌患者新辅助化疗后行保乳手术的可行性分析［J］. 海军军医大学学报， 2025 ， 46 （ 1 ）： 141 - 146 . doi： 10.16781/j.CN31-2187/R.20230307 http://dx.doi.org/10.16781/j.CN31-2187/R.20230307 .

中国抗癌协会乳腺癌专业委员会 . 中国抗癌协会乳腺癌诊治指南与规范（2017年版）［J］. 中国癌症杂志， 2017 ， 27 （ 9 ）： 695 - 759 . doi： 10.19401/j.cnki.1007-3639.2017.09.004 http://dx.doi.org/10.19401/j.cnki.1007-3639.2017.09.004 .

杨小湜，王阳，李秀君，等 . SF-36量表的信度和效度评价［J］. 解剖科学进展， 2009 ， 15 （ 4 ）： 383 - 385 .

尚卿，王海鹏，王静 . 1992-2021年中国女性乳腺癌发病和死亡的年龄-时期-队列模型分析及预测［J］. 解放军医学杂志， 2025 ， 50 （ 4 ）： 436 - 443 . doi： 10.11855/j.issn.0577-7402.1919.2025.0324 http://dx.doi.org/10.11855/j.issn.0577-7402.1919.2025.0324 .

Shinjit M ， Abhishek H ， Sergei B . Triple-negative breast cancer： the current aspects of pathogenesis and therapies ［J］. BioNanoscience ， 2022 ， 12 （ 4 ）： 1404 - 1435 . doi： 10.1007/s12668-022-00991-1 http://dx.doi.org/10.1007/s12668-022-00991-1 .

狄淑群，潘华，狄挺松，等 . 浸润性乳腺癌改良根治术后化疗患者复发转移的影响因素及预测模型建立［J］. 医学研究与战创伤救治， 2024 ， 37 （ 2 ）： 166 - 171 . doi： 10.16571/j.cnki.2097-2768.2024. 02.010 http://dx.doi.org/10.16571/j.cnki.2097-2768.2024.02.010 .

杨建军 . 保乳手术与改良根治术治疗早期乳腺癌的效果比较［J］. 妇儿健康导刊， 2025 ， 4 （ 6 ）： 103 - 106 . doi： 10.3969/j.issn.2097-115X.2025.06.021 http://dx.doi.org/10.3969/j.issn.2097-115X.2025.06.021 .

赵迪，马建萍，杨红梅 . 新辅助化疗后保乳术与改良根治术治疗Ⅱb~Ⅲa期乳腺癌的临床疗效对比［J］. 中国临床医生杂志， 2024 ， 52 （ 8 ）： 957 - 960 . doi： 10.3969/j.issn.2095-8552.2024.08.020 http://dx.doi.org/10.3969/j.issn.2095-8552.2024.08.020 .

谢新美，闭月琼，吴斯敏，等 . 局部晚期乳腺癌新辅助化疗联合保乳手术治疗的临床疗效观察［J］. 广西医科大学学报， 2022 ， 39 （ 6 ）： 959 - 962 . doi： 10.16190/j.cnki.45-1211/r.2022.06.019 http://dx.doi.org/10.16190/j.cnki.45-1211/r.2022.06.019 .

杨业勤，潘嫚 . 表柔比星联合紫杉醇治疗乳腺癌的疗效分析［J］. 中国卫生标准管理， 2022 ， 13 （ 15 ）： 135 - 139 . doi： 10.3969/j.issn.1674-9316.2022.15.028 http://dx.doi.org/10.3969/j.issn.1674-9316.2022.15.028 .

14］陈春龙，吴祥虎，丁皓 . 改良根治术与保乳手术治疗对乳腺癌患者的临床疗效比较［J］. 贵州医药， 2025 ， 49 （ 6 ）： 922 - 924 . doi： 10.3969/j.issn.1000-744X.2025.06.025 http://dx.doi.org/10.3969/j.issn.1000-744X.2025.06.025 .

施海虹，戴磊，陈琳 . 腔镜乳腺癌改良根治术与开放手术的临床效果比较［J］. 中华实验外科杂志， 2024 ， 41 （ 8 ）： 1806 - 1810 . doi： 10.3760/cma.j.cn421213-20230828-01306 http://dx.doi.org/10.3760/cma.j.cn421213-20230828-01306 .

刘海亮，张贤周，王昆明 . 保乳手术联合前哨淋巴活检术治疗早期乳腺癌患者的效果观察［J］. 黑龙江医学， 2025 ， 49 （ 9 ）： 1064 - 1066 . doi： 10.3969/j.issn.1004-5775.2025.09.012 http://dx.doi.org/10.3969/j.issn.1004-5775.2025.09.012 .

王晓娇，练孝春，韩涛，等 . 新辅助化疗联合保乳术对早期乳腺癌患者的临床运用分析［J］. 河北医学， 2022 ， 28 （ 11 ）： 1887 - 1891 . doi： 10.3969/j.issn.1006-6233.2022.11.026 http://dx.doi.org/10.3969/j.issn.1006-6233.2022.11.026 .

Zhang J ， Wei Q ， Dong D ， et al . The role of TPS， CA125， CA15-3 and CEA in prediction of distant metastasis of breast cancer ［J］. Clin Chim Acta ， 2021 ， 52 （ 3 ）： 19 - 25 . doi： 10.1016/j.cca.2021.08.027 http://dx.doi.org/10.1016/j.cca.2021.08.027 .

王浩宇，石文达，赵晓彬，等 . 乳腺X线征象、ADC值联合血清CA125、CEA水平预测乳腺癌新辅助化疗后腋窝淋巴结病理状态的价值［J］. 放射学实践， 2024 ， 39 （ 9 ）： 1178 - 1183 . doi： 10.13609/j.cnki.1000-0313.2024.09.010 http://dx.doi.org/10.13609/j.cnki.1000-0313.2024.09.010 .

容亚娟，张坤，黄雪，等 . 超声血流参数联合血清CA153、miR-335水平在乳腺癌诊断中的应用［J］. 国际免疫学杂志， 2025 ， 48 （ 2 ）： 138 - 143 . doi： 10.3760/cma.j.issn.1673-4394.2025.02.004 http://dx.doi.org/10.3760/cma.j.issn.1673-4394.2025.02.004 .

田二军，王滨，姜楠 . 血清CYFRA21-1、CA125、CA153、CEA对乳腺癌的诊断及预测术后复发的价值［J］. 河南医学研究， 2024 ， 33 （ 11 ）： 2037 - 2040 . doi： 10.3969/j.issn.1004-437X.2024. 11.029 http://dx.doi.org/10.3969/j.issn.1004-437X.2024.11.029 .

杨乐，张宇，徐鑫，等 . CEUS-FNAC联合血清CA153、VEGF检测对乳腺癌转移SLN的诊断价值［J］. 分子诊断与治疗杂志， 2025 ， 17 （ 5 ）： 927 - 930 . doi： 10.3969/j.issn.1674-6929.2025. 05.035 http://dx.doi.org/10.3969/j.issn.1674-6929.2025.05.035 .

肖强 . 保乳术与改良根治术治疗绝经期乳腺癌患者的疗效及对心理状态、远期生活质量的影响［J］. 辽宁医学杂志， 2023 ， 37 （ 2 ）： 13 - 15 .

Views

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Impact of different breast cancer surgery combined with intensity modulated radiation therapy on the living quality and sexual life of female patients

Comparison of MRI and whole subserial section in assessing tumor bed after neoadjuvant chemotherapy for breast cancer

Influencing factors of intercostobrachial nerve injury during modified radical mastectomy

Exploration of the molecular mechanism of Compound Danshen Tablets in radiosensitivity of breast cancer based on network pharmacology and molecular docking techniques

Molecular mechanism of saikosaponin-d in reversing radioresistance of breast cancer

Related Author

LU Changcun

CHEN Junguo

WANG Ge

YANG Zhenzhou

YU Xian

ZHANG Hui

XIAO He

ZHANG Qichuan

Related Institution

Cancer Center,Institute of Surgery Research,Daping Hospital,Third Military Medical University

Medical Education Laboratory,Training Department,Third Military Medical University

Department of Radiology, Second Hospital Affiliated to Army Medical University

Department of Breast Surgery,First Hospital Affiliated to Army Medical University

Department of Thyroid and Breast Surgery,Anqing Municipal Hospital

⁰